Strategic Planning Group LLC Purchases 785 Shares of Danaher Co. (NYSE:DHR)

Strategic Planning Group LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 5.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,276 shares of the conglomerate’s stock after buying an additional 785 shares during the quarter. Strategic Planning Group LLC’s holdings in Danaher were worth $3,277,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new position in Danaher during the 4th quarter worth about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC bought a new position in shares of Danaher during the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new position in Danaher during the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of a number of analyst reports. Stifel Nicolaus upped their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Jefferies Financial Group lowered their price target on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Robert W. Baird reduced their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $284.14.

Danaher Trading Down 10.0 %

Shares of NYSE:DHR opened at $223.12 on Thursday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52-week low of $223.00 and a 52-week high of $281.70. The stock has a market cap of $161.15 billion, a price-to-earnings ratio of 42.58, a PEG ratio of 4.43 and a beta of 0.83. The business has a 50-day moving average price of $236.09 and a 200-day moving average price of $253.66.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter last year, the firm posted $2.09 earnings per share. Equities analysts predict that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.48%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.